Thank you for sponsoring the Alzheimer’s Accountability and Investment Act (H.R. 620) to extend the Alzheimer's Bypass Budget for ten more years. Frontotemporal degeneration, or FTD, is one of the related dementias included in the Alzheimer's Bypass budget. FTD is an underdiagnosed brain disorder that affects more than 60,000 people in the United States. It can impact behavior, decision-making, personality, language, and/or movement, irreversibly changing a person’s ability to relate to loved ones or function at work. Average life expectancy is 7 to 13 years. There are currently no treatments to slow the progress of this disease. Much progress has been made since the first Alzheimer's Bypass Budget was released in 2015, culminating in the FDA's recent approvals of the first ever disease-modifying treatments for Alzheimer's. This progress must continue until treatments are developed for FTD and all the dementias covered by the Bypass Budget. By sponsoring the Alzheimer's Accountability and Investment Act (H.R. 620), you are helping to ensure that this progress will continue and bringing hope to everyone affected by FTD. Please continue encouraging your colleagues to join you in support of this crucial piece of legislation. Thank you. For more information on FTD or this campaign, contact AFTD at info@theaftd.org or 866.507.7222.

We appreciate your support for the Alzheimer’s Accountability and Investment Act (H.R. 620) to extend the Alzheimer's Bypass Budget for another decade. Frontotemporal degeneration (FTD), a type of dementia covered by the Alzheimer's Bypass budget, affects over 60,000 individuals in the United States. FTD can significantly impact behavior, personality, language, and movement, greatly altering one's relationships and ability to function. The average life expectancy is 7 to 13 years. Unfortunately, there are no treatments currently available to slow down its progression. Significant advancements have been achieved since the initial Alzheimer's Bypass Budget in 2015, including the recent FDA approvals of the first disease-modifying treatments for Alzheimer's. It is crucial to sustain this momentum until effective treatments are developed not only for Alzheimer's but also for FTD and other dementias encompassed by the Bypass Budget. By endorsing the Alzheimer's Accountability and Investment Act (H.R. 620), you are playing a pivotal role in ensuring the continuation of this progress and fostering hope for all individuals impacted by FTD. We urge you to rally your colleagues to unify in support of this vital legislation. Thank you for your dedication. If you seek further information on FTD or wish to support this cause, please reach out to AFTD at info@theaftd.org or 866.507.7222.

Please vote YES to pass the Alzheimer’s Accountability and Investment Act (H.R. 620) to extend the Alzheimer's Bypass Budget for ten more years and ensure that funding for dementia research at NIH can continue. Frontotemporal degeneration, or FTD, is one of the related dementias included in the Alzheimer's Bypass budget. FTD is an underdiagnosed brain disorder that affects more than 60,000 people in the United States. It can impact behavior, decision-making, personality, language, and/or movement, irreversibly changing a person’s ability to relate to loved ones or function at work. Average life expectancy is 7 to 13 years. There are currently no treatments to slow the progress of this disease. Much progress has been made since the first Alzheimer's Bypass Budget was released in 2015, culminating in the FDA's recent approvals of the first ever disease-modifying treatments for Alzheimer's. We must continue this progress until treatments are developed for FTD and all forms of dementia covered by the Bypass Budget. Passing the Alzheimer's Accountability and Investment Act (H.R. 620), will help to maintain this progress and bring hope to the individuals and families facing FTD and the related dementias included in the Bypass Budget. Thank you. For more information on FTD or this campaign contact AFTD at info@theaftd.org or 866.507.7222.